MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Tag: Low-Grade Serous Ovarian Cancer

Low-Grade Serous Ovarian Cancer

Latest news

Tag

news

Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-up

A 2-year follow-up of the ENGOT-OV60/GOG-3052/RAMP 201 trial confirms that the combination of avutometinib and defactinib offers sustained benefit and manageable safety in recurrent low-grade serous ovarian cancer, particularly in patients

Sep 21, 2026
Clinical Updates

Avutometinib Plus Defactinib: A Promising Treatment for Recurrent Low-Grade Serous Ovarian Cancer

This phase II study demonstrates that the combination of avutometinib and defactinib offers significant clinical benefit with manageable safety in recurrent low-grade serous ovarian cancer, particularly in KRAS-mutant tumors.

Sep 8, 2025

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story